Use of Multiple Doses of Intravenous Infusion of Umbilical Cord-Mesenchymal Stem Cells for the Treatment of Adult Patients with Severe COVID-19-Related Acute Respiratory Distress Syndrome: Literature Review
Objectives. Acute respiratory distress syndrome (ARDS) is a critical complication in severe COVID-19 patients. The intravenous infusion (IVF) of umbilical cord- (UC-) mesenchymal stem cells (MSCs), validated to substantially reduce the release of several inflammatory cytokines in vivo, was also show...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-01-01
|
| Series: | Stem Cells International |
| Online Access: | http://dx.doi.org/10.1155/2023/7179592 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832555295466848256 |
|---|---|
| author | Po-Ren Hsueh Sung-Jung Ho Po-Chuen Hsieh I-Min Liu Shio-Shin Jean |
| author_facet | Po-Ren Hsueh Sung-Jung Ho Po-Chuen Hsieh I-Min Liu Shio-Shin Jean |
| author_sort | Po-Ren Hsueh |
| collection | DOAJ |
| description | Objectives. Acute respiratory distress syndrome (ARDS) is a critical complication in severe COVID-19 patients. The intravenous infusion (IVF) of umbilical cord- (UC-) mesenchymal stem cells (MSCs), validated to substantially reduce the release of several inflammatory cytokines in vivo, was also shown to exhibit benefits in improving hypoxemia among severe COVID-19 patients. A single dose of IVF-UC-MSCs therapy for severe COVID-19 patients was shown to alleviate the initial ARDS severity, but have 50%–67% case-fatality rates. In Taiwan, few adult patients with severe COVID-19-induced ARDS receiving compassionate adjuvant treatment consisting of either a single dose (1–10 × 106 cells/kg body weight (kg BW)) or three doses (5 × 106 cells/kg BW in each dose) of IVF-UC-MSCs had good outcomes. However, the optimal dosage and rounds of IVF-UC-MSCs administration for the treatment of severe COVID-19 patients with ARDS are undetermined. Methods. We reviewed the 2020–2022 PubMed literature database concerning the clinical efficacy of IVF-UC-MSCs among severe COVID-19 patients. Results. The data of COVID-19 case series in the PubMed literature revealed a notable heterogeneity in the therapeutic dosage (a single dose: 1–10 × 106 cells/kg BW; and three doses: 50–200 × 106 cells/kg BW in each dose) and the post-ARDS days of IVF-UC-MSCs administration (a single dose: 1–12; and multiple doses: 5–14) for the treatment of severe COVID-19-associated ARDS. The survival rates among these severe COVID-19 patients ranged from 50% to 76%. However, an overall rate of 93.1% of significant improvement in hypoxemia was observed for the COVID-19 survivors receiving IVF-UC-MSCs at the initial ARDS stage. Conclusions. According to our analysis, the ideal treatment dosage of IVF-UC-MSCs for severe COVID-19-induced ARDS is likely 5 × 106 cells/kg BW for three cycles within 5 days of ARDS onset in severe COVID-19 patients. |
| format | Article |
| id | doaj-art-e959b88a9e754bd498262d664fd46687 |
| institution | Kabale University |
| issn | 1687-9678 |
| language | English |
| publishDate | 2023-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Stem Cells International |
| spelling | doaj-art-e959b88a9e754bd498262d664fd466872025-02-03T05:48:40ZengWileyStem Cells International1687-96782023-01-01202310.1155/2023/7179592Use of Multiple Doses of Intravenous Infusion of Umbilical Cord-Mesenchymal Stem Cells for the Treatment of Adult Patients with Severe COVID-19-Related Acute Respiratory Distress Syndrome: Literature ReviewPo-Ren Hsueh0Sung-Jung Ho1Po-Chuen Hsieh2I-Min Liu3Shio-Shin Jean4Departments of Laboratory Medicine and Internal MedicineDivision of Pulmonary MedicineDepartment of PharmacyDepartment of PharmacyDepartment of PharmacyObjectives. Acute respiratory distress syndrome (ARDS) is a critical complication in severe COVID-19 patients. The intravenous infusion (IVF) of umbilical cord- (UC-) mesenchymal stem cells (MSCs), validated to substantially reduce the release of several inflammatory cytokines in vivo, was also shown to exhibit benefits in improving hypoxemia among severe COVID-19 patients. A single dose of IVF-UC-MSCs therapy for severe COVID-19 patients was shown to alleviate the initial ARDS severity, but have 50%–67% case-fatality rates. In Taiwan, few adult patients with severe COVID-19-induced ARDS receiving compassionate adjuvant treatment consisting of either a single dose (1–10 × 106 cells/kg body weight (kg BW)) or three doses (5 × 106 cells/kg BW in each dose) of IVF-UC-MSCs had good outcomes. However, the optimal dosage and rounds of IVF-UC-MSCs administration for the treatment of severe COVID-19 patients with ARDS are undetermined. Methods. We reviewed the 2020–2022 PubMed literature database concerning the clinical efficacy of IVF-UC-MSCs among severe COVID-19 patients. Results. The data of COVID-19 case series in the PubMed literature revealed a notable heterogeneity in the therapeutic dosage (a single dose: 1–10 × 106 cells/kg BW; and three doses: 50–200 × 106 cells/kg BW in each dose) and the post-ARDS days of IVF-UC-MSCs administration (a single dose: 1–12; and multiple doses: 5–14) for the treatment of severe COVID-19-associated ARDS. The survival rates among these severe COVID-19 patients ranged from 50% to 76%. However, an overall rate of 93.1% of significant improvement in hypoxemia was observed for the COVID-19 survivors receiving IVF-UC-MSCs at the initial ARDS stage. Conclusions. According to our analysis, the ideal treatment dosage of IVF-UC-MSCs for severe COVID-19-induced ARDS is likely 5 × 106 cells/kg BW for three cycles within 5 days of ARDS onset in severe COVID-19 patients.http://dx.doi.org/10.1155/2023/7179592 |
| spellingShingle | Po-Ren Hsueh Sung-Jung Ho Po-Chuen Hsieh I-Min Liu Shio-Shin Jean Use of Multiple Doses of Intravenous Infusion of Umbilical Cord-Mesenchymal Stem Cells for the Treatment of Adult Patients with Severe COVID-19-Related Acute Respiratory Distress Syndrome: Literature Review Stem Cells International |
| title | Use of Multiple Doses of Intravenous Infusion of Umbilical Cord-Mesenchymal Stem Cells for the Treatment of Adult Patients with Severe COVID-19-Related Acute Respiratory Distress Syndrome: Literature Review |
| title_full | Use of Multiple Doses of Intravenous Infusion of Umbilical Cord-Mesenchymal Stem Cells for the Treatment of Adult Patients with Severe COVID-19-Related Acute Respiratory Distress Syndrome: Literature Review |
| title_fullStr | Use of Multiple Doses of Intravenous Infusion of Umbilical Cord-Mesenchymal Stem Cells for the Treatment of Adult Patients with Severe COVID-19-Related Acute Respiratory Distress Syndrome: Literature Review |
| title_full_unstemmed | Use of Multiple Doses of Intravenous Infusion of Umbilical Cord-Mesenchymal Stem Cells for the Treatment of Adult Patients with Severe COVID-19-Related Acute Respiratory Distress Syndrome: Literature Review |
| title_short | Use of Multiple Doses of Intravenous Infusion of Umbilical Cord-Mesenchymal Stem Cells for the Treatment of Adult Patients with Severe COVID-19-Related Acute Respiratory Distress Syndrome: Literature Review |
| title_sort | use of multiple doses of intravenous infusion of umbilical cord mesenchymal stem cells for the treatment of adult patients with severe covid 19 related acute respiratory distress syndrome literature review |
| url | http://dx.doi.org/10.1155/2023/7179592 |
| work_keys_str_mv | AT porenhsueh useofmultipledosesofintravenousinfusionofumbilicalcordmesenchymalstemcellsforthetreatmentofadultpatientswithseverecovid19relatedacuterespiratorydistresssyndromeliteraturereview AT sungjungho useofmultipledosesofintravenousinfusionofumbilicalcordmesenchymalstemcellsforthetreatmentofadultpatientswithseverecovid19relatedacuterespiratorydistresssyndromeliteraturereview AT pochuenhsieh useofmultipledosesofintravenousinfusionofumbilicalcordmesenchymalstemcellsforthetreatmentofadultpatientswithseverecovid19relatedacuterespiratorydistresssyndromeliteraturereview AT iminliu useofmultipledosesofintravenousinfusionofumbilicalcordmesenchymalstemcellsforthetreatmentofadultpatientswithseverecovid19relatedacuterespiratorydistresssyndromeliteraturereview AT shioshinjean useofmultipledosesofintravenousinfusionofumbilicalcordmesenchymalstemcellsforthetreatmentofadultpatientswithseverecovid19relatedacuterespiratorydistresssyndromeliteraturereview |